WebGOG 99: Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG; Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92 … WebMar 1, 2011 · Request PDF On Mar 1, 2011, M. Funk and others published Have PORTEC 1 and GOG 99 changed practice patterns in the United States? Find, read and cite all …

Endometrial cancer - null regimens - HemOnc.org

WebSep 21, 2016 · The GOG Gynecologic Oncology Committee centrally reviewed all patient eligibility data without knowledge of outcome. The primary end point used to compare the … Web– GOG 99 – ASTEC/EN 5 – ... Keys et al. Gynecol Oncol 2004; 92;744 . Overall Results • Median follow-up of surviving patients – 68 months. • The 24-month cumulative incidence … intel ax211 wifi driver

Review: Clinical Trials Outcome for Chemotherapy in ... - Springer

WebMay 19, 2024 · This year, an estimated 61,880 women in the United States will be diagnosed with uterine cancer. From 2006 to 2015, the number of women in the US diagnosed with EC increased by 1% and 2% each year for white and black women, respectively. The 5‑year survival rates for white and black women with the disease are … WebGOG Protocol 204 Monk et al Abstract No: LBA 5504 [email protected] GOG Studies in Advanced and Recurrent Cervical Cancer Historical Background and Introduction Moore DH et al J Clin Oncol 2004;22:3113-3119. • GOG 169 (Cisplatin versus Cisplatin + Paclitaxel) – N = 260 – % prior Chemo/RT = 30% and 24% – RR = 19% vs 36% (P= 0.002) WebNout et al; JCO, 2011 Nout et al; JCO, 2011 Nout et al; JCO, 2011 . ... GOG 99 Trial •Stage IB - II ... No Vaginal Brachytherapy •Regimen 2 No further Treatment Keys et al. Gynecol Oncol 2004; 92;744. Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand intel b150m supported cpus